Fresenius SE KGaA (XTRA:FRE) Faces Recall Scrutiny, Is The Valuation Gap Still Intact?

Fresenius SE KGaA (XTRA:FRE) is facing investor scrutiny after its Fresenius Medical Care Renal Therapies subsidiary initiated two Class II recalls affecting dialysis tubing and liquid acid concentrate products distributed across multiple global markets.

At around €46.24 per share, Fresenius SE KGaA has seen a 15.28% 90 day share price return, while the year to date share price performance is down 3.12%. The longer view shows a 67.60% three year total shareholder return that points to momentum building over time despite current recall related headlines.

Balance recall risk at Fresenius SE KGaA against other potential opportunities by scanning a curated set of 229 resilient stocks with low risk scores with more resilient profiles.

Fresenius SE KGaA has rebounded sharply, and recall headlines are already in the price for some investors. The next step is simple: do current valuation metrics still leave meaningful upside, or has the rerating largely played out?

Most Popular Narrative: 15.6% Undervalued

Against the last close of €46.24, the most followed narrative for Fresenius SE KGaA points to a fair value of €54.79. As a result, the recall noise sits against a backdrop of a wider valuation gap anchored on long term fundamentals and forecast cash generation.

Increasing demand for healthcare services due to the growing elderly global population and the rise in chronic diseases (such as diabetes, hypertension, and kidney disorders) is driving sustained organic revenue growth across Fresenius's hospital (Helios) and dialysis (Kabi) businesses, evidenced by the company's raised full-year organic revenue guidance. (Likely to impact revenue and top-line growth.)

See why 35 investors see Fresenius SE KGaA as 16% undervalued.

Result: Fair Value of €54.79 (UNDERVALUED)

Still, if wage and supply costs outpace the pricing power of Fresenius SE KGaA, or if biosimilar competition squeezes key therapies, the current undervalued thesis could quickly look fragile.

Find out about the key risks to this Fresenius SE KGaA narrative.

Next Steps

Mixed about Fresenius SE KGaA after the recalls and valuation gap narrative. If you want to move fast and reach your own judgment, start with the full breakdown of its 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Fresenius SE KGaA?

If Fresenius SE KGaA has your attention but you want stronger diversification, use the Simply Wall Street Screener to surface fresh ideas before others do.

• Target quality at a discount by scanning the 172 high quality undervalued stocks that combine strong fundamentals with prices that some investors may be overlooking.
• Build a steadier income base by reviewing the 160 dividend fortresses that focus on higher yielding payouts backed by underlying business strength.
• Strengthen your core holdings by checking the list of solid balance sheet and fundamentals (198 results) to find companies with healthier finances that can better handle shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com